MorphoSys is dedicated to become a fully integrated biopharmaceutical company. Our business strategy brings more value for patients, investors and partners.

First MorphoSys-antibody approved
Tremfya® (Guselkumab) now available in US, Europe and Canada!

We develop exceptional, innovative biopharmaceuticals
to improve the lives of patients suffering
from serious diseases.

Find out more about our therapeutic pipeline.

More Info

MorphoSys's vision

MorphoSys's mission is to make exceptional, innovative biopharmaceuticals to improve the lives of patients suffering from serious diseases. Our focus is on cancer. Innovative technologies and smart development strategies are central to our approach.

learn more about the company

08/07/2019
MorphoSys and Vivoryon Therapeutics Enter Agreement on Small Molecule...
03/07/2019
MorphoSys's Licensing Partner GSK Initiates Phase 3 Clinical Program...
03/07/2019
Ad hoc: MorphoSys Increases Financial Guidance for 2019 Following a...
24/06/2019
Correction of a release from 24/06/2019, 20:36 CET/CEST - Ad hoc:...
24/06/2019
MorphoSys Appoints Jean-Paul Kress, M.D., as New Chief Executive Officer
24/06/2019
Ad hoc: MorphoSys Appoints Jean-Paul Kress, M.D., as New Chief Executive...
22/06/2019
MorphoSys Presents Primary Analysis Data from L-MIND Study of Tafasitamab...
14/06/2019
MorphoSys's Licensee Janssen Announces Top-line Phase 3 Results for...
23/05/2019
MorphoSys to Present at Upcoming Investor Conferences
22/05/2019
MorphoSys AG Reports Outcome of Annual General Meeting 2019

June 25, 2019
Webcast
Meet the Team Event
New York, NY, U.S.

Full details

 

 

 

 

Interview with
Simon Moroney, CEO